Skip to content
Moderate

Peptide Law in Delaware

Last reviewed

Status overview

Delaware is a moderate-tier state for compounded peptide access as of September 2026. The April 15 federal reclassification of 12 peptides to an interim evaluation tier sets the national legal floor. Delaware adds registration requirements on top of it: an out-of-state pharmacy that ships prescription drugs to a Delaware patient must hold a Delaware nonresident pharmacy license, designate a Delaware registered agent, and submit an inspection report approved by the Board of Pharmacy.

No Delaware statute creates a distinct “peptide” category. Peptides are governed by federal drug law plus Delaware’s pharmacy chapter at Title 24, Chapter 25 of the Delaware Code and its telehealth chapter at Title 24, Chapter 60. What separates Delaware from permissive states is licensing friction rather than enforcement posture: the state requires affirmative licensure by every out-of-state pharmacy serving its residents, including 503B outsourcing facilities that compound sterile drugs.

PeptidesBeat identified no Delaware-specific enforcement action against peptide sellers as of September 2026. That distinguishes Delaware from states such as Connecticut, where the Attorney General has pursued gray-market GLP-1 sellers since 2025.

On September 18, 2026, twenty state attorneys general led by Alabama Attorney General Steve Marshall released a letter signed September 17, 2026, asking the Secretary of State and the National Security Council to treat Chinese-sourced ingredients in compounded GLP-1 drugs as a national-security matter; Delaware was not among the signatories. See the explainer and Alabama’s tracker entry.

Regulatory landscape

Pharmacy regulation in Delaware sits with the Board of Pharmacy inside the Division of Professional Regulation. The operative rules are published at 24 DE Admin. Code 2500. Key provisions for September 2026:

  • Nonresident pharmacy license. Under 24 Del. C. § 2535, a pharmacy located in another state that delivers, dispenses, or distributes a prescription drug to a patient in Delaware must obtain a nonresident pharmacy license from the Board. To qualify, the applicant must hold an unencumbered license in every jurisdiction where it is or was licensed, have no disciplinary history, and submit the most recent inspection report approved by the Board — either from the home-state licensing authority or, if none is available that satisfies the statute, from the National Association of Boards of Pharmacy verified pharmacy program.
  • Registered agent. 24 Del. C. § 2536 requires a nonresident pharmacy to designate a Delaware registered agent for service of process. A pharmacy that fails to do so appoints the Secretary of State as its agent by default. In effect, Delaware requires out-of-state compounders to maintain a legal presence in the state before serving Delaware patients.
  • Shipping-container notice. Section 2535(b) requires a written notice inside any shipped prescription container alerting the patient that a drug’s effectiveness may be affected by exposure to extremes of heat, cold, or humidity, and that a local or toll-free telephone service staffed by a registered pharmacist is available for questions. For temperature-sensitive injectables, including peptide solutions, that notice is mandatory rather than discretionary.
  • 503B outsourcing facility licensure. 24 Del. C. § 2540A requires manufacturers, wholesale distributors, and outsourcing facilities to be licensed by the Board. An outsourcing facility applicant must supply ownership and key-personnel information, a recent good-manufacturing-practice inspection report acceptable to the Board, proof of licensure or registration in its home state, and must meet the Board’s rules. Delaware’s statutory definition of an outsourcing facility is limited to a facility registered with the FDA under section 503B of the federal Food, Drug, and Cosmetic Act that is doing business within or into Delaware — and the statute requires a Delaware wholesaler license before the facility may apply as an outsourcing facility.
  • Compounding standards. Delaware law defines compounding as the preparation, assembling, packaging, or labeling of a drug resulting from a practitioner’s prescription, or for research, teaching, or chemical analysis, and not for sale or dispensing (24 Del. C. § 2502 definitions, Chapter 25, Subchapter I). The Board’s regulations at 24 DE Admin. Code 2500 set the operative sterile and non-sterile compounding standards that pharmacies and outsourcing facilities must meet.
  • Telehealth prescribing. Delaware regulates telehealth under Chapter 60. 24 Del. C. § 6003 prohibits a health-care provider from delivering services by telehealth without a provider-patient relationship, which must include verification of the patient’s location and identity, disclosure and validation of the provider’s credentials, informed consent, and establishment of a diagnosis through acceptable medical practice. 24 Del. C. § 6004 requires the provider to satisfy at least one of four conditions before diagnosis and treatment, such as an in-person examination, a Delaware-licensed provider present with the patient, a diagnosis by audio or visual communication, or adherence to professional-society standards for telehealth practice. Once the relationship is established, subsequent treatment of the same patient by the same provider is not subject to those limitations.
  • Practitioner licensure. Chapter 60 defines the distant site as a location where a health-care provider legally allowed to practice in Delaware is located. Practitioners prescribing to Delaware patients are expected to hold Delaware licensure; Delaware’s statute does not create a general out-of-state telehealth registration pathway independent of licensure.

Why Delaware is a moderate tier

Delaware’s requirements are procedural rather than prohibitive. Nothing in state law names peptides, restricts compounding of specific peptides, or directs the Attorney General to pursue sellers. What Delaware does require is that every out-of-state pharmacy serving Delaware residents hold a state license, carry a registered agent, and submit an inspection report — a set of hurdles that some national compounders decline to clear, particularly smaller operations that ship to a handful of states.

The comparison with neighboring states is instructive. Connecticut’s restrictive rating flows from Attorney General enforcement against gray-market GLP-1 sales. Delaware’s moderate rating flows from registration requirements: friction that narrows the field of suppliers without criminalizing lawful compounding. The underlying tension between federal compounding approval and state-level access rules is the same gap state boards are navigating nationwide.

What the April 15 reclassification and July PCAC vote mean for Delaware

The FDA’s April 15 reclassification does not alter Delaware statutes directly, but it changes which national compounders are willing to ship to Delaware residents. At the July 23-24 PCAC meeting, the advisory committee recommended six peptides for the 503A Bulks List — BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon — and declined to recommend DSIP. The FDA’s final 503A Bulks List decision remains pending, and additional peptides are queued for future review.

For Delaware the practical effect runs through licensing. A compounder must clear the state’s nonresident license and registered-agent requirements before serving Delaware patients at all, regardless of how the federal bulks-list question resolves. Federal compounding approval and state pharmacy licensure are separate frameworks, and Delaware’s requirements will not change based on the PCAC outcome.

What this means in practice

  • Prescription path. A valid patient-specific prescription from a licensed practitioner is required. Telehealth prescribing is permitted where the Chapter 60 provider-patient relationship requirements are met, and the prescribing practitioner should hold Delaware licensure.
  • Compounding pharmacy access. Verify that an out-of-state pharmacy holds a current Delaware nonresident pharmacy license before assuming it can ship to Delaware. The Division of Professional Regulation publishes a public license verification tool.
  • Lead time. Licensing, registered-agent, and inspection-report requirements commonly add 7-14 days beyond standard fulfillment timelines, and some national compounders decline Delaware business rather than carry the additional registrations.
  • Quality watch. Endotoxin and purity failures have driven compounded-peptide recalls in 2026, and independent safety organizations have flagged quality gaps in the wellness-peptide supply chain. Delaware’s inspection-report requirement for nonresident pharmacies gives the Board a documented basis for evaluating an out-of-state compounder’s history.
  • Post-PCAC outlook. Final 503A rulemaking will settle the compounding status of the six recommended peptides. Delaware’s licensure requirements will not change as a result, so the state’s access picture is set more by who is willing to register than by the federal decision.

Key contacts

Pharmacy considerations

When a compounding pharmacy serves Delaware, confirm the nonresident license is current and that a registered agent is designated under 24 Del. C. § 2536 before placing an order. Because Delaware’s license conditions turn on an applicant’s disciplinary history and inspection record, the license itself is a partial quality signal — but it is not a substitute for verifying that an injectable peptide was compounded under current USP standards. The practical risk for Delaware patients is less about federal policy than about state registration, inspection history, and whether a given supplier has chosen to maintain a Delaware license at all.

This page was last updated September 10, 2026. State pharmacy regulations change, often without public notice. Verify current requirements with the compounding pharmacy before ordering, and check the PeptidesBeat State Tracker for the latest updates.